908 Devices (NASDAQ:MASS) Receives Sell (E+) Rating from Weiss Ratings

Weiss Ratings reissued their sell (e+) rating on shares of 908 Devices (NASDAQ:MASS) in a research note released on Friday morning,Weiss Ratings reports.

Several other equities analysts also recently weighed in on MASS. Leerink Partnrs downgraded shares of 908 Devices from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 13th. Stephens reaffirmed an “overweight” rating and set a $6.00 price target on shares of 908 Devices in a report on Wednesday, January 15th. Leerink Partners reaffirmed a “market perform” rating and set a $4.00 price target (down previously from $12.00) on shares of 908 Devices in a report on Wednesday, November 13th. Finally, Stifel Nicolaus reduced their price objective on shares of 908 Devices from $17.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $5.33.

908 Devices Price Performance

Shares of NASDAQ:MASS opened at $2.76 on Friday. 908 Devices has a 1-year low of $1.81 and a 1-year high of $7.56. The company has a market capitalization of $96.11 million, a P/E ratio of -1.56 and a beta of 0.99. The firm’s 50 day simple moving average is $2.51 and its two-hundred day simple moving average is $2.94.

Institutional Investors Weigh In On 908 Devices

Several institutional investors and hedge funds have recently modified their holdings of MASS. Drive Wealth Management LLC bought a new stake in shares of 908 Devices during the third quarter valued at approximately $50,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in 908 Devices in the third quarter worth $190,000. Charles Schwab Investment Management Inc. increased its position in 908 Devices by 14.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 220,477 shares of the company’s stock worth $765,000 after purchasing an additional 28,015 shares during the last quarter. 49 Wealth Management LLC increased its position in 908 Devices by 16.2% in the third quarter. 49 Wealth Management LLC now owns 31,099 shares of the company’s stock worth $108,000 after purchasing an additional 4,343 shares during the last quarter. Finally, Townsquare Capital LLC bought a new stake in 908 Devices in the third quarter worth $50,000. Institutional investors own 88.06% of the company’s stock.

About 908 Devices

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.